There were no differences in other treatments between the AKI group and the non-AKI group, though interferon beta was more frequently used in the AKI group (169 cases, 29.5%) than in the non-AKI group (168 cases, 19.5%). The gene discussed is IFNB1; the disease is acute kidney injury.